Meiji Seika Starts Phase I Trial for ME3241 in Australia
Meiji Seika Pharma Co., Ltd. (Headquarters: Chuo-ku, Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) announced today that it has initiated a Phase I clinical...
Tag : Meiji Seika Pharma
Meiji Seika Pharma Gets Approval for Domestic KOSTAIVE® Production
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan, President and Representative Director: Daikichiro Kobayashi) announced today that it has received approval for a partial amendment...